New clinical research study offers hope to Crohn’s and Colitis sufferers in Central Florida
Brazikumab is a type of protein called an antibody that may help prevent and reduce inflammation. This study could be the answer you are looking for if you have Crohn’s or Colitis.
(Please note, you can call in for more information about this study and even apply over the phone. Call John Robins on (863) 397 3646.)
How does brazikumab work?
The white blood cells that make up your immune system use different types of proteins, called interleukins, to send messages to each other. These proteins help to organize immune responses. In both Crohn’s disease and Colitis, a particular kind of interleukin, called interleukin-23 (IL-23), attracts new white blood cells to areas of inflammation, making it worse. Brazikumab is designed to stick to IL-23. This helps to stop IL-23 from binding to white blood cells, meaning they can’t get involved in inflammation. If IL-23 is stopped from binding to white blood cells, that should significantly reduce the symptoms making patients feel better.
Previous clinical research has shown that brazikumab is a promising treatment for Crohn’s disease. The reason for the study is that researchers still need more information to confirm brazikumab can be established as an effective therapy option for people with Crohn’s disease.
Previous clinical research has shown that brazikumab is a promising treatment for both Crohn’s and Colitis. The reason for the study is that researchers still need more information to confirm brazikumab can be established as an effective therapy option for sufferers.
Treatment includes two periods: induction and maintenance. If you complete both, it will last 52 weeks. You will be asked to attend the study clinic for appointments and receive various tests and assessments during the treatment period.
If you are selected for this double-blind study and given brazikumab your results will be compared against a dummy treatment. The process is designed to confirm that the treatment works.
To be accepted for the study, you must be between 18 and 80 years old. Have been diagnosed with Crohn’s or Colitis and have had no response or an insufficient response to previous treatment.
Crohn’s and Colitis are highly debilitating conditions for many sufferers, and the opportunity to find a treatment is highly sought after. This study is your opportunity to be part of the cure. Participating in this study may offer the treatment to give you the relief you seek.
If you meet the criteria above, complete the application form below and be ready to be contacted by a member of our team. If accepted, we will provide all the support and care you need to complete the study.